Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim

Adult patients with primary immune thrombocytopenia requiring first-line treatment typically receive corticosteroids, which are associated with low response rates and many potential side effects. In a retrospective analysis of two 6-month, placebo-controlled, phase III trials, corticosteroid use dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Michel, Marc, te Boekhorst, Peter A W, Janssens, Ann, Pabinger-Fasching, Ingrid, Sanz, Miguel A, Nie, Kun, Kreuzbauer, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Maney Publishing 2011
Materias:
Hematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178451/
https://www.ncbi.nlm.nih.gov/pubmed/21902890
http://dx.doi.org/10.1179/102453311X13025568942005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178451/
https://www.ncbi.nlm.nih.gov/pubmed/21902890
http://dx.doi.org/10.1179/102453311X13025568942005

Ejemplares similares